Ekaterina Novikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekaterina Novikova has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Adam D. Griesemer
1 shared publication- Ai C. Ra
Applied Bioinformatics Laboratories, New York University Grossman School of Medicine, New York, NY, USA
1 shared publication - Allegra Iliadi Alexiou
Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA
1 shared publication - Amanda W. Lund
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
1 shared publication - Andre L. Moreira
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
1 shared publication Anoma Nellore
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 73-83
Efficacy of laughter therapy in elderly patients with late-life depression and dementia: a systematic review and meta-analysis
The proportion of older people in the global population is increasing. High rates of depression and dementia, as well as the risks associated with pharmacotherapy, highlight the need for new, safe and effective therapeutic approaches. One such promising method is laughter therapy (LT). Objective: to evaluate, in this systematic review and meta-analysis, the effectiveness of laughter therapy (LT) in older patients with late-onset depression and dementia. Material and methods. A systematic literature search was conducted in the PubMed/MEDLINE and ProQuest databases (up to 28 May 2024). Studies were selected that included patients aged 60 years and over with late-onset depression, neurodegenerative diseases (Alzheimer’s disease, Pick’s disease) or dementia who underwent LT. Results. Five studies were included in the final analysis. In patients with late-onset depression undergoing LT, the increase in vitality was comparable to the results in the control group. The meta-analysis revealed a strong trend towards increased life satisfaction compared with the control group. LT reduces psychotic symptoms of dementia; however, it shows conflicting results regarding distress, agitation and aggression, and a worsening of disinhibition is also noted. LT has no significant effect on the behavioral and psychological symptoms of dementia as a whole. Standard treatment methods improve vitality more significantly in dementia. Conclusion. LT is a promising non-pharmacological treatment for late-onset dementia and depression, which may be preferable in cases where the use of pharmacotherapy is limited. However, LT requires monitoring for agitation and aggression in patients with dementia.
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 73-83
Open AccessEfficacy of laughter therapy in elderly patients with late-life depression and dementia: a systematic review and meta-analysis
The proportion of older people in the global population is increasing. High rates of depression and dementia, as well as the risks associated with pharmacotherapy, highlight the need for new, safe and effective therapeutic approaches. One such promising method is laughter therapy (LT). Objective: to evaluate, in this systematic review and meta-analysis, the effectiveness of laughter therapy (LT) in older patients with late-onset depression and dementia. Material and methods. A systematic literature search was conducted in the PubMed/MEDLINE and ProQuest databases (up to 28 May 2024). Studies were selected that included patients aged 60 years and over with late-onset depression, neurodegenerative diseases (Alzheimer’s disease, Pick’s disease) or dementia who underwent LT. Results. Five studies were included in the final analysis. In patients with late-onset depression undergoing LT, the increase in vitality was comparable to the results in the control group. The meta-analysis revealed a strong trend towards increased life satisfaction compared with the control group. LT reduces psychotic symptoms of dementia; however, it shows conflicting results regarding distress, agitation and aggression, and a worsening of disinhibition is also noted. LT has no significant effect on the behavioral and psychological symptoms of dementia as a whole. Standard treatment methods improve vitality more significantly in dementia. Conclusion. LT is a promising non-pharmacological treatment for late-onset dementia and depression, which may be preferable in cases where the use of pharmacotherapy is limited. However, LT requires monitoring for agitation and aggression in patients with dementia.
- 12 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6786) , eads1246
Transcription factor Etv3 controls the tolerogenic function of dendritic cells
Dendritic cells (DCs) facilitate the maintenance of immunological tolerance in the steady state. We report that transcription factor Etv3 is preferentially expressed in mature DCs, including tissue-derived migratory DCs (migDCs), and facilitates their homeostatic maturation and CCR7-dependent migration. Mice with global or DC-specific deletion of Etv3 manifested the expansion of CD25 low regulatory T (T reg ) cells, spontaneous activation of conventional T cells, and multiorgan T cell infiltration. Etv3 deficiency exacerbated TLR7-driven systemic lupus erythematosus (SLE)–like disease, supporting the reported genetic association of human ETV3 with SLE. Etv3-deficient migDCs up-regulated multiple costimulatory molecules, including OX40 ligand (OX40L/TNFSF4), whose blockade partially rescued the T reg cell abnormalities. These results identify Etv3 as an essential regulator of the tolerogenic function of DCs and implicate it in the regulation of human autoimmunity.
- 12 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6786) , eads1246
Transcription factor Etv3 controls the tolerogenic function of dendritic cells
Dendritic cells (DCs) facilitate the maintenance of immunological tolerance in the steady state. We report that transcription factor Etv3 is preferentially expressed in mature DCs, including tissue-derived migratory DCs (migDCs), and facilitates their homeostatic maturation and CCR7-dependent migration. Mice with global or DC-specific deletion of Etv3 manifested the expansion of CD25 low regulatory T (T reg ) cells, spontaneous activation of conventional T cells, and multiorgan T cell infiltration. Etv3 deficiency exacerbated TLR7-driven systemic lupus erythematosus (SLE)–like disease, supporting the reported genetic association of human ETV3 with SLE. Etv3-deficient migDCs up-regulated multiple costimulatory molecules, including OX40 ligand (OX40L/TNFSF4), whose blockade partially rescued the T reg cell abnormalities. These results identify Etv3 as an essential regulator of the tolerogenic function of DCs and implicate it in the regulation of human autoimmunity.
- Open Access
Coordinated circulating and tissue-based T cell responses precede xenograft rejection
Despite the life-saving successes of solid organ transplantation, the number of individuals needing organ transplant far exceeds the number of organs available for use each year. Porcine xenotransplantation, or the use of pig organs for transplantation in people, holds substantial promise but xenograft rejection in humans is poorly understood. T cell rejection by the host immune system is a major challenge for human allografts and may limit the longevity of porcine xenografts. To study the xenograft rejection, we evaluated T cell responses and repertoire dynamics across tissues following porcine thymokidney transplantation in a decedent model over 61 days after bilateral native kidney nephrectomy. Despite induction with anti-thymocyte globulin and ongoing immune suppression consisting of rituximab, corticosteroids, calcineurin inhibition, and mycophenolate mofetil, human T cell infiltration of the xenograft was observed and was associated with xenograft dysfunction. Longitudinal analysis of T cell clonotypes in biopsies of thymokidney revealed accumulation of clonal human CD4 and CD8 T cell responses. Moreover, circulating activated T cells, including circulating T follicular helper (cTfh), were xeno-reactive and increased in frequency around rejection events. We confirmed clonal dominance of a single CD8 clonotype – identified as donor-reactive in a mixed lymphocyte reaction – in the circulation leading up to the acute cellular rejection event. Following re-treatment with anti-thymocyte globulin and intensification of corticosteroids, the T cell clonotypes were dramatically diminished in frequency in thymokidney and lymph nodes, though not eliminated. Over time of observation, the T cell clonotypes were shared across multiple compartments, including xenograft, circulation and lymph nodes and formed clonal families with known xeno-reactive clonotypes, suggesting a coordinated immune response against a limited pool of antigenic targets. Together, these data demonstrate T cell repertoire dynamics across tissues in the setting of xenograft rejection and highlight opportunities for early surveillance, prediction and potential intervention. One-sentence summary: After pig-to-human kidney xenotransplantation, xenoreactive T cells form clonotypic families across blood, graft, and lymphoid tissues, indicating a coordinated and targeted response.
Open AccessCoordinated circulating and tissue-based T cell responses precede xenograft rejection
Despite the life-saving successes of solid organ transplantation, the number of individuals needing organ transplant far exceeds the number of organs available for use each year. Porcine xenotransplantation, or the use of pig organs for transplantation in people, holds substantial promise but xenograft rejection in humans is poorly understood. T cell rejection by the host immune system is a major challenge for human allografts and may limit the longevity of porcine xenografts. To study the xenograft rejection, we evaluated T cell responses and repertoire dynamics across tissues following porcine thymokidney transplantation in a decedent model over 61 days after bilateral native kidney nephrectomy. Despite induction with anti-thymocyte globulin and ongoing immune suppression consisting of rituximab, corticosteroids, calcineurin inhibition, and mycophenolate mofetil, human T cell infiltration of the xenograft was observed and was associated with xenograft dysfunction. Longitudinal analysis of T cell clonotypes in biopsies of thymokidney revealed accumulation of clonal human CD4 and CD8 T cell responses. Moreover, circulating activated T cells, including circulating T follicular helper (cTfh), were xeno-reactive and increased in frequency around rejection events. We confirmed clonal dominance of a single CD8 clonotype – identified as donor-reactive in a mixed lymphocyte reaction – in the circulation leading up to the acute cellular rejection event. Following re-treatment with anti-thymocyte globulin and intensification of corticosteroids, the T cell clonotypes were dramatically diminished in frequency in thymokidney and lymph nodes, though not eliminated. Over time of observation, the T cell clonotypes were shared across multiple compartments, including xenograft, circulation and lymph nodes and formed clonal families with known xeno-reactive clonotypes, suggesting a coordinated immune response against a limited pool of antigenic targets. Together, these data demonstrate T cell repertoire dynamics across tissues in the setting of xenograft rejection and highlight opportunities for early surveillance, prediction and potential intervention. One-sentence summary: After pig-to-human kidney xenotransplantation, xenoreactive T cells form clonotypic families across blood, graft, and lymphoid tissues, indicating a coordinated and targeted response.